ArticleJournal of pharmacy & bioallied sciences
Primary Brain Tumor Radiotherapy with Concurrent and Adjuvant Temozolomide: Its Outcomes in Terms of Survival and Toxicity.
Article in Journal of pharmacy & bioallied sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To assess the outcome of primary brain tumor radiotherapy with concurrent and adjuvant temozolomide. Material and Methods: A total of 42 patients who were histologically proven primary malignant brain tumor with nonmetastatic, ECOG (Eastern Cooperative Oncology Group) performance status 0, 1, and 2 were enrolled in this study. Results: All patients underwent craniotomy with gross total excision (GTE) 66.7% and partial excision 33.3%. Post craniotomy, patients were diagnosed as grade II 28.6%, grade III 23.8%, grade IV 42.9%, and glio-sarcoma 4.8%. Post radiotherapy with concurrent and adjuvant temozolomide, two years of overall survival were 83.3%, 60%, and 25% in grade II, grade III, and high-grade glioma, respectively. Conclusion: This study concluded that radiotherapy is an integral part of treatment in primary malignant brain tumor. Temozolomide (TMZ) in concurrent and adjuvant setting had additional survival benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.